Ratings by BofA Securities (Geoff Meacham)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/12/2026 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 12/2/2025 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2025 | Vir Biotechnology | VIR | Upgrade | Buy (Neutral) |
4.44 (9.55) |
115.09% | Details | |
| 8/8/2025 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2025 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Kymera Therapeutics | KYMR | Upgrade | Buy (Neutral) |
29.64 (83.49) |
181.68% | Details | |
| 4/8/2025 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2025 | IGM Biosciences | IGMS | Downgrade | Underperform (Neutral) |
1.12 (1.27) |
13.39% | Details | |
| 4/2/2025 | Neumora Therapeutics | NMRA | Downgrade | Underperform (Buy) |
1.00 (3.02) |
202% | Details | |
| 4/2/2025 | Neumora Therapeutics | NMRA | Downgrade | Underperform (Buy) |
1.00 (1.00) |
0% | Details | |
| 3/10/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Sana Biotechnology | SANA | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2025 | Neumora Therapeutics | NMRA | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2024 | Lyell Immunopharma | LYEL | Downgrade | Underperform (Buy) |
0.95 (22.46) |
2264.21% | Details | |
| 10/23/2024 | Amylyx Pharmaceuticals inc. | AMLX | Upgrade | Buy (Neutral) |
4.53 (13.85) |
205.74% | Details | |
| 10/18/2024 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2024 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2024 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 5/13/2024 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2024 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
52.92 (73.05) |
38.04% | Details | |
| 5/3/2024 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
25.58 (14.82) |
-42.06% | Details | |
| 4/17/2024 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2024 | Regeneron Pharma | REGN | Maintain | Underperform (N/A) |
|
Details | ||
| 4/12/2024 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2024 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/13/2024 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2024 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2024 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2024 | Kymera Therapeutics | KYMR | Downgrade | Neutral (Buy) |
25.35 (29.64) |
16.92% | Details | |
| 1/3/2024 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (Buy) |
52.76 (60.29) |
14.27% | Details | |
| 1/3/2024 | LianBio | LIAN | Downgrade | Underperform (Buy) |
4.37 (0.32) |
-92.68% | Details | |
| 12/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Tyra Biosciences | TYRA | Downgrade | Neutral (Buy) |
14.78 (35.04) |
137.08% | Details | |
| 12/15/2023 | IGM Biosciences | IGMS | Downgrade | Neutral (Buy) |
6.50 (1.27) |
-80.46% | Details | |
| 11/20/2023 | LianBio | LIAN | Maintain | Buy (N/A) |
|
Details | ||
| 11/20/2023 | Turnstone Biologics | TSBX | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2023 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2023 | Amgen | AMGN | New Coverage | Neutral (N/A) |
271.25 (369.53) |
36.23% | Details | |
| 10/10/2023 | Neumora Therapeutics | NMRA | New Coverage | Buy (N/A) |
11.94 (1.00) |
-91.62% | Details | |
| 10/6/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2023 | Gilead Sciences | GILD | Upgrade | Buy (Neutral) |
73.94 (143.93) |
94.66% | Details | |
| 9/8/2023 | Vir Biotechnology | VIR | Downgrade | Neutral (Buy) |
11.56 (4.44) |
-61.59% | Details | |
| 8/15/2023 | Turnstone Biologics | TSBX | New Coverage | Buy (N/A) |
11.73 (0.36) |
-96.93% | Details | |
| 8/7/2023 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/21/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2023 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Buy (N/A) |
7.41 (3.31) |
-55.33% | Details | |
| 6/30/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2023 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | IGM Biosciences | IGMS | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Century Therapeutics | IPSC | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Caribou Biosciences Inc. | CRBU | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2023 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/5/2023 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 4/3/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2023 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2023 | Graphite Bio Inc | GRPH | Downgrade | Underperform (Neutral) |
2.20 (3.18) |
44.55% | Details | |
| 1/18/2023 | Graphite Bio Inc | GRPH | Downgrade | Neutral (Buy) |
2.05 (3.18) |
55.12% | Details | |
| 1/5/2023 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
35.54 (13.85) |
-61.03% | Details | |
| 1/4/2023 | LianBio | LIAN | Maintain | (N/A) |
|
Details | ||
| 1/4/2023 | 89bio Inc. | ETNB | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2023 | Seagen | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2023 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2023 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2023 | Merck | MRK | Upgrade | Buy (Neutral) |
111.14 (115.79) |
4.18% | Details | |
| 1/4/2023 | Pfizer | PFE | Downgrade | Neutral (Buy) |
51.26 (27.05) |
-47.23% | Details | |
| 12/14/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2022 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
88.54 (143.93) |
62.56% | Details | |
| 12/12/2022 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 12/5/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 11/30/2022 | Sana Biotechnology | SANA | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2022 | Rani Therapeutics Holdsing s | RANI | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2022 | Lyell Immunopharma | LYEL | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2022 | Caribou Biosciences Inc. | CRBU | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | Omeros Corp. | OMER | Downgrade | Underperform (Neutral) |
3.28 (11.54) |
251.83% | Details | |
| 11/1/2022 | Inovio Pharmaceuticals | INO | Downgrade | Underperform (Neutral) |
2.16 (1.74) |
-19.44% | Details | |
| 9/29/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/29/2022 | IGM Biosciences | IGMS | New Coverage | Buy () |
18.42 (1.27) |
-93.11% | Details | |
| 7/5/2022 | Seagen | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2022 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/21/2022 | Seagen | SGEN | Maintain | Buy (N/A) |
|
Details | ||
| 6/21/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 6/8/2022 | Omeros Corp. | OMER | Downgrade | Neutral (Buy) |
2.42 (11.54) |
376.86% | Details | |
| 6/2/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 6/1/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/25/2022 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2022 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2022 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2022 | Omeros Corp. | OMER | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | 89bio Inc. | ETNB | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Sana Biotechnology | SANA | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Vaxxinity | VAXX | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Graphite Bio Inc | GRPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | LianBio | LIAN | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Inovio Pharmaceuticals | INO | Maintain | Neutral (N/A) |
|
Details | ||
| 5/17/2022 | Rani Therapeutics Holdsing s | RANI | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 4/4/2022 | Regeneron Pharma | REGN | Maintain | Underperform (N/A) |
|
Details | ||
| 3/31/2022 | Checkmate Pharmaceuticals | CMPI | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 3/11/2022 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2022 | Omeros Corp. | OMER | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2022 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2022 | Kiniksa | KNSA | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/3/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2022 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/21/2022 | CureVac | CVAC | Downgrade | Underperform (Neutral) |
21.85 (4.66) |
-78.67% | Details | |
| 1/21/2022 | Acumen Pharmaceuticals, Inc. | ABOS | Upgrade | Buy (Neutral) |
4.99 (3.31) |
-33.67% | Details | |
| 1/21/2022 | Inovio Pharmaceuticals | INO | Upgrade | Neutral (Underperform) |
4.10 (1.74) |
-57.56% | Details | |
| 1/21/2022 | Moderna | MRNA | Upgrade | Neutral (Underperform) |
167.52 (52.52) |
-68.65% | Details | |
| 1/14/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/13/2022 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2022 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 1/10/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2022 | Regeneron Pharma | REGN | Downgrade | Underperform (Neutral) |
616.82 (759.86) |
23.19% | Details | |
| 1/5/2022 | Pfizer | PFE | Upgrade | Buy (Neutral) |
54.53 (27.05) |
-50.39% | Details | |
| 1/5/2022 | Amgen | AMGN | Downgrade | Neutral (Buy) |
227.84 (369.53) |
62.19% | Details | |
| 12/29/2021 | Kiniksa | KNSA | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/22/2021 | LianBio | LIAN | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2021 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/6/2021 | Vaxxinity | VAXX | New Coverage | Buy (N/A) |
8.53 (0.01) |
-99.88% | Details | |
| 11/26/2021 | LianBio | LIAN | New Coverage | Buy (N/A) |
15.57 (0.32) |
-97.94% | Details | |
| 11/16/2021 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2021 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2021 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/15/2021 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 10/11/2021 | Tyra Biosciences | TYRA | New Coverage | Buy (N/A) |
16.26 (35.04) |
115.5% | Details | |
| 10/6/2021 | Checkmate Pharmaceuticals | CMPI | Upgrade | Buy (Neutral) |
3.86 (10.50) |
172.02% | Details | |
| 10/4/2021 | Omeros Corp. | OMER | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2021 | Inovio Pharmaceuticals | INO | Downgrade | Underperform (Neutral) |
8.40 (4.10) |
-51.19% | Details | |
| 9/10/2021 | Kymera Therapeutics | KYMR | Upgrade | Buy (Neutral) |
64.17 (83.49) |
30.11% | Details | |
| 9/10/2021 | BridgeBio Pharma | BBIO | Upgrade | Buy (Neutral) |
50.87 (65.36) |
28.48% | Details | |
| 8/17/2021 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 8/10/2021 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 8/6/2021 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 8/2/2021 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 7/28/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/26/2021 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Neutral (N/A) |
17.08 (4.99) |
-70.78% | Details | |
| 7/19/2021 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/13/2021 | Century Therapeutics | IPSC | New Coverage | Buy (N/A) |
27.25 (2.56) |
-90.61% | Details | |
| 7/12/2021 | Lyell Immunopharma | LYEL | New Coverage | Buy (N/A) |
15.88 (22.46) |
41.44% | Details | |
| 7/6/2021 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
25.40 (13.84) |
-45.51% | Details | |
| 6/22/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/8/2021 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2021 | Biogen | BIIB | Upgrade | Neutral (Underperform) |
286.14 (184.87) |
-35.39% | Details | |
| 5/19/2021 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 4/30/2021 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 4/30/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2021 | Kiniksa | KNSA | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/1/2021 | Moderna | MRNA | Downgrade | Underperform (Neutral) |
173.16 (167.52) |
-3.26% | Details | |
| 1/26/2021 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2021 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2021 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2021 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | Genfit | GNFT | Maintain | Underperform (N/A) |
|
Details | ||
| 1/5/2021 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2021 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/11/2020 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 12/9/2020 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/7/2020 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/3/2020 | Moderna | MRNA | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2020 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/9/2020 | Biogen | BIIB | Downgrade | Underperform (Neutral) |
324.77 (286.14) |
-11.89% | Details | |
| 11/4/2020 | Biogen | BIIB | Upgrade | Neutral (Underperform) |
247.01 (184.87) |
-25.16% | Details | |
| 10/29/2020 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2020 | Omeros Corp. | OMER | New Coverage | Buy (N/A) |
11.08 (11.54) |
4.15% | Details | |
| 9/15/2020 | Kymera Therapeutics | KYMR | New Coverage | Neutral (N/A) |
32.78 (64.17) |
95.76% | Details | |
| 9/1/2020 | Checkmate Pharmaceuticals | CMPI | New Coverage | Neutral (N/A) |
15.58 (10.50) |
-32.61% | Details | |
| 8/19/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 7/15/2020 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/25/2020 | Regenxbio Inc. | RGNX | New Coverage | Buy (N/A) |
35.31 (8.65) |
-75.5% | Details | |
| 6/25/2020 | Genfit | GNFT | New Coverage | Underperform (N/A) |
5.91 (4.85) |
-17.94% | Details | |
| 6/10/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2020 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2020 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2020 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/15/2020 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2020 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2020 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2020 | Amgen | AMGN | Upgrade | Buy (Neutral) |
215.11 (369.53) |
71.79% | Details | |
| 12/11/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 11/22/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/20/2019 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Underperform (N/A) |
|
Details |
